A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC)

Journal of Immunotherapy

Volumn 33, Issue 7, 2010, Pages 716-722

  Atchison, Elizabeth ^a   Eklund, John ^a   Martone, Brenda ^b   Wang, Lili ^a   Gidron, Adi ^a   MacVicar, Gary ^a   Rademaker, Alfred ^c   Goolsby, Charles ^d   Marszalek, Laura ^d   Kozlowski, James ^e   Smith, Norm ^e   Kuzel, Timothy M ^a  

^a NW Univ Feinberg School of Medicine   (United States)

^b Research Office Robert H Lurie Comprehensive Cancer Center   (United States)

^c Division of Biostatistics   (United States)

^d Flow Cytometry Core ^*  (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

denileukin diftitox depletion of T regulatory lymphocytes; interleukin 2; T regulatory lymphocytes

Indexed keywords

DENILEUKIN DIFTITOX; DIPHENHYDRAMINE; PARACETAMOL; RECOMBINANT INTERLEUKIN 2; SUNITINIB;

ADULT; ARTICLE; BLOOD CELL COUNT; CANCER REGRESSION; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; FLOW CYTOMETRY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INFECTION; KIDNEY CARCINOMA; KIDNEY SARCOMA; LYMPHOCYTE PROLIFERATION; MALE; METASTASIS; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; THROMBOSIS; TRANSIENT ACANTHOLYTIC DERMATOSIS; VASCULAR DISEASE; VASCULAR LEAK SYNDROME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL COUNT; CELL PROLIFERATION; CELL SEPARATION; DIPHTHERIA TOXIN; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY NEOPLASMS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 77955175181     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181e4752e     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: a Cancer J Clinicians. 2008;58:4.
2. Colli JL, Busby JE, Amling CL. Renal cell carcinoma rates compared with health status and behavior in the United States. Urology. 2009;73:431-436.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
4. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
5. Klapper JA, Downey SG, Smith FO, et al. High-dose inter-leukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293-301.
6. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
7. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
8. Fyfe GA, Fisher RI, Rosenberg SA, et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1996;14:2410-2411.
9. Bronte V, Mocellin S. Suppressive influences in the immune response to cancer. J Immunother. 2009;32:1-11.
10. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423-5434.
11. Thornton AM, Shevach EM. CD4+CD25+ immunoregula-tory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188: 287-296.
12. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med. 2001;193: 1311-1318.
13. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163:5211-5218.
14. Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24:1169-1177.
15. Javia LR, Rosenberg SA. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother. 2003;26:85-93.
16. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-4772.
17. Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276.
18. Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007;13:2075-2081.
19. Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol. 2000;27:194-203.
20. Van der Vliet HJ, van der Vliet HJ, Koon HB, et al. Effects of the administration of high-dose interleukin-2 on immunoregu-latory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res. 2007;13:2100-2108.
21. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19:3477-3482.
22. Berman D, Wolchok J, Weber J, et al. Increases in peripheral blood absolute lymphocyte count (ALC) associated with clinical activity in patients with advanced melanoma treated with ipilimumab. In: 2009 American Society of Clinical Oncology Annual Meeting. Orlando Florida USA; 2009.
23. Monaghan SA, Peterson LC, James C, et al. Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL). Cytometry Part B, Clinical Cytometry. 2003;56:30-42.
24. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res. 2004;10:6302S-6303S.
25. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115: 3623-3633.
26. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood. 2008;112: 610-618.
27. Rasku MA, Clem AL, Telang S, et al. Transient T cell depletion causes regression of melanoma metastases. J Transla-tional Med. 2008;6:12.
28. Attia P, Maker AV, Haworth LR, et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005;28:582-592.
29. McDermott DF, Atkins MB. Immunotherapy of metastatic renal cell carcinoma. Cancer J (Sudbury, MA). 2008;14: 320-324.
30. Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother. 2009;32:181-185.
31. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;98: 2566-2575.
32. Cormier SA, Taranova AG, Bedient C, et al. Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol. 2006;79: 1131-1139.
33. Al Murri AM, Bartlett JM, Canney PA, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94:227-230.
34. Crumley AB, Stuart RC, McKernan M, et al. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol. 2008;23:e325-e329.
35. Forrest LM, McMillan DC, McArdle CS, et al. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2005;92:1834-1836.
36. McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22:881-886.